SEC Form 4 · accession 0001450324-19-000007
AIM ImmunoTech Inc. · AIM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Stewart Appelrouth
Director
Period of report
Jan 28, 2019
Accepted (ET)
Jan 30, 2019 · 12:35 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000946644
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options to buy Common StockF1 | $0.22 | Jan 28, 2019 | A | 207,343 | A | Jan 28, 2019 | Jan 28, 2029 | Common Stock | 207,343 | 207,343 | D |
| Options to buy Common StockF2 | $0.22 | Jan 28, 2019 | A | 50,000 | A | Jan 28, 2019 | Jan 28, 2029 | Common Stock | 50,000 | 50,000 | D |
Explanation of responses
- F1This option is being issued to senior management for a voluntary 100% deferral of Director's fees.
- F2This option is being issued to senior management for serving as Chair on committees in the year 2019.